Lv11
60 积分 2025-04-07 加入
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
5天前
已完结
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
2个月前
已完结
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma
2个月前
已关闭
皖公网安备34019202002308
